Figure 6.

Effects of CUR-DOX-LCL on the proliferation of C26 murine colon carcinoma cells.

Notes: The results show cell proliferation at 48 hours after incubation of C26 cells with 0.05–0.25 μM DOX, as a free form, DOX-LCL, and LCL co-encapsulated with CUR and DOX at a molar ratio of (A) DOX:CUR =1:9 and (B) DOX:CUR =1:167. Data are presented as the mean ± standard deviation of triplicate measurements. The results are expressed as percentage of inhibition of C26 cell proliferation following DOX, DOX-LCL and CUR-DOX-LCL treatments, compared to the proliferation of control cells (untreated cells). Significance was considered at values of P<0.05 (ns, P>0.05; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).

Abbreviations: CUR, curcumin; DOX, doxorubicin; LCL, long-circulating liposomes; ns, not significant.